Richard McCormick

Richard J. McCormick is a partner in the New York office of Mayer Brown’s Intellectual Property practice. He has represented innovator pharmaceutical, biotech, and medical device companies in patent infringement and licensing dispute matters, including Hatch-Waxman litigations and inter partes reviews in the Patent Office.

Richard has also advised clients on FDA regulatory issues implicating the patent laws, prepared patent validity/enforceability and freedom-to-operate opinions, and performed patent due diligence in connection with pre-litigation assessments, IP in-licensing and M&A transactions.

Before beginning his legal career, Richard was a Ph.D. candidate in biochemistry before becoming a research associate in the Department of Molecular Biology at Princeton University and the Department of Pediatric Oncology at the Dana-Farber Cancer Institute.

Richard’s knowledge base in the life sciences encompasses biochemistry, molecular and cellular biology, molecular genetics, protein chemistry, pharmacology, pharmaceutical formulation and controlled drug delivery, pharmaceutical solid state chemistry, small molecule drug discovery, RNA interference and antisense technology, and the production and characterization of recombinant therapeutic proteins (including antibodies).

Education :

• Boston College Law School, JD
• Fordham University, BS

Admissions :

• New York
• Massachusetts

Experience :

• Genzyme v. Genentech and City of Hope, C.D. Cal. (2015) and related Inter Partes Reviews
• Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals v. Genentech and City of Hope, C.D. Cal. (2015) and related Inter Partes Review
• Genentech Inc. v. Glaxo Group Ltd., GlaxoSmithKline and Human Genome Sciences, C.D. Cal. (2011)
• Alza Corp. and Janssen Pharmaceutica v. Mylan Labs. et al., D. Vt. (2002) and Fed. Cir. (2004)
• Nextec Applications v. Marmot Mountain, Ltd, S.D. Cal. (2001)